8-K: Cartesian Therapeutics Appoints June Seymour as CAO

Cartesian Therapeutics, Inc. announced the appointment of June Seymour as its new Chief Accounting Officer, effective October 27, 2025.

Summary

• Cartesian Therapeutics, Inc. appointed June Seymour as Chief Accounting Officer, effective upon her full-time employment commencement on October 27, 2025.
• Ms. Seymour, age 48, brings over two decades of financial leadership experience in the life sciences sector, including previous roles at DNAnexus, Neogene Therapeutics (through its sale to AstraZeneca), Autolus Ltd., and Ernst & Young LLP.
• Her compensation package includes an annual base salary of $385,000, an annual performance bonus targeted at 35% of her base salary (prorated for 2025), and an $80,000 sign-on bonus.
• She was granted an option to purchase 50,000 shares of the company's common stock, with an exercise price equal to the closing price on the grant date, vesting over a four-year period.
• Severance provisions include six months of continued base salary, a pro-rata annual bonus, and up to six months of COBRA coverage if her employment is terminated without cause or she resigns for good reason.
• Ms. Seymour has agreed to restrictive covenants, including non-competition and non-solicitation of customers, suppliers, and employees for 12 months following termination.
• Blaine Davis, the company's Chief Financial Officer, will continue to be designated as both the Principal Financial Officer and Principal Accounting Officer.

Sentiment

Score: 7

Explanation: The appointment of a highly experienced Chief Accounting Officer is a positive step for corporate governance and financial reporting, indicating a strengthening of the management team. While not directly impacting financial performance, it signals stability and adherence to best practices.

Positives

• The appointment of June Seymour, a highly experienced financial leader with over two decades in the life sciences sector, strengthens the company's financial reporting and accounting capabilities.
• Ms. Seymour's background includes experience with M&A integration (Neogene Therapeutics' sale to AstraZeneca) and specializing in U.S. transactions for European life sciences companies at Ernst & Young LLP, indicating strong technical and transactional expertise.
• The structured compensation package, including equity options, aligns Ms. Seymour's incentives with the company's long-term performance.

Risks

• No specific operational or financial risks for the company were mentioned in this filing. The risks are standard for executive employment agreements, such as potential for executive departure, which is partially mitigated by restrictive covenants.

Future Outlook

The company anticipates strengthening its financial leadership and reporting capabilities with Ms. Seymour's expertise. Her stock options are designed to vest over a four-year period, aligning her incentives with long-term company performance.

Management Comments

• The Board of Directors appointed June Seymour as the Company's Chief Accounting Officer.

Industry Context

The life sciences sector, particularly for publicly traded companies, requires robust financial reporting and compliance expertise. The appointment of a seasoned Chief Accounting Officer like Ms. Seymour, with extensive experience in both public accounting and industry roles, reflects a common strategic move to bolster financial infrastructure and ensure adherence to complex regulatory requirements, especially given her background in U.S. transactions involving European life sciences companies.

Comparison to Industry Standards

• Ms. Seymour's compensation package, including a base salary of $385,000, a 35% target bonus, and a 50,000-share option grant, appears competitive for a Chief Accounting Officer role at a publicly traded life sciences company of similar size and stage, aligning with industry benchmarks for attracting experienced talent.
• Her background, including leadership roles at DNAnexus, Neogene Therapeutics (acquired by AstraZeneca), and Autolus Ltd., demonstrates a career trajectory consistent with high-caliber financial executives in the biotech and pharmaceutical industry.
• The inclusion of standard restrictive covenants (non-compete, non-solicitation) and an indemnification agreement is typical for executive employment agreements in the U.S. market, reflecting best practices in corporate governance and executive protection.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Enhanced confidence in financial reporting and corporate governance due to the appointment of an experienced financial executive.
• Employees: Addition of a new senior leader to the finance team, potentially bringing new expertise and processes.
• Regulatory Bodies: Improved compliance posture with the SEC and other financial regulations due to strengthened accounting leadership.

Next Steps

• June Seymour will commence full-time employment as Chief Accounting Officer on October 27, 2025.
• Her stock options will begin vesting 12 months from the grant date (October 27, 2025).

Key Dates

Keywords

Cartesian Therapeutics, RNAC, Chief Accounting Officer, CAO, June Seymour, Executive Appointment, Life Sciences Finance, SEC Filing, Corporate Governance, Financial Reporting